Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on June 3, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 124,000 shares of Class A common stock and restricted stock units (RSUs) for 65,925 shares of Class A common stock to seventeen (17) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employmen...
Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference BRISBANE, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference, which is taking place in Miami Beach, FL from June 9 – 11, 2025. The management team will also p...
Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans BRISBANE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has entered into a new credit facility providing for up to $500 million of term loans with its current partner Oxford Finance LLC (“Oxford”). The new credit facility will replace Vera’s existing $50 million...
Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week 36 (p
Capital Bank Launches New Digital Banking Platform in Partnership with Q2, Advancing Innovation and Customer-Focused Growth ROCKVILLE, Md., May 19, 2025 (GLOBE NEWSWIRE) -- Capital Bank, N.A. has officially launched its new digital banking platform, powered by Q2, a leader in digital transformation for financial services. The upgrade delivers a secure, modern experience for business customers and marks a major step in the Bank’s ongoing digital evolution. Known for its agile, growth-oriented approach, Capital Bank continues to invest in technology that enhances efficiency and meets the d...
Capital Bank Adds Veteran Delaware Commercial Banking Team Expanding Presence in the Region ROCKVILLE, Md., May 19, 2025 (GLOBE NEWSWIRE) -- Capital Bancorp (NASDAQ: CBNK) announced today the expansion of its Commercial Banking operations in Delaware with the addition of several highly experienced relationship managers. This strategic move marks a key milestone in the Bank’s Mid-Atlantic growth strategy, positioning Capital Bank to serve more businesses across the state of Delaware and surrounding areas. Located in Southern Delaware, Ritchie Francia is a seasoned commercial banker with d...
PubMatic to Participate in Upcoming Financial Conferences NO-HEADQUARTERS/REDWOOD CITY, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- PubMatic, Inc. (Nasdaq: PUBM), an independent technology company delivering digital advertising’s supply chain of the future, today announced that members of its management team are scheduled to participate and host investor meetings at the following upcoming financial conferences: Jefferies Public Technology Conference on Wednesday May 28, 2025. Management will host one-on-one meetings. Evercore ISI “Nothing But Net” Internet Investors Summit on Wednesday May ...
Texas Capital Foundation Awards $250,000 to Texas Nonprofits Annual Honors Award program celebrates four organizations that are building a stronger Texas DALLAS, May 14, 2025 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital, today announced the recipients of its 2025 Honors Awards. Launched in 2022, the Honors Awards are a signature initiative of the Texas Capital Foundation, awarding $250,000 in total annually to four organizations dedicated to addressing community needs across the state. “We are proud to honor four nonprofits as...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on May 5, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 111,750 shares of Class A common stock and restricted stock units (RSUs) for 62,575 shares of Class A common stock to eleven (11) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.